This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Carcinoma in situ of cervix uteri자궁경부의 제자리암 (자궁경부제자리암)

📋 Contents and key points
A. Classification codesICD-10: D06 | D06.0 Carcinoma in situ of endocervix | D06.1 Carcinoma in situ of exocervix | D06.7 Carcinoma in situ of other parts of cervix | D06.9 Carcinoma in situ of cervix, unspecified | Special Copayment Reduction V193 (5% copayment, for 5 years from the registration date)
B. SynonymsCervical intraepithelial neoplasia grade 3 (CIN 3), cervical high-grade squamous intraepithelial lesion (HSIL), cervical intraepithelial carcinoma, carcinoma in situ of the endocervix, cervical adenocarcinoma in situ (AIS), high-grade cervical dysplasia
C. Adult onsetVery high — after onset of sexual activity; CIN3/CIS mainly at ages 25-45; develops over 5-15 years after HPV infection; incidence markedly reduced in HPV-vaccinated women
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References
1. History summaryDevelopment of the Papanicolaou smear (1943); Reagan (1953) established the CIN classification system; zur Hausen (2008 Nobel Prize) identified the link between HPV and cervical cancer; introduction of LEEP (1989).
2. Causes summaryHPV types 16/18 (70-80% of cases); smoking; immunosuppression; early sexual debut and multiple sexual partners; long-term oral contraceptive use.
3. Genetics summaryHPV16 E6 → p53 degradation; HPV18 E7 → pRb inactivation; TP53, PIK3CA somatic; PTEN loss; Lynch syndrome (MSH6); TERT reactivation.
4. Epidemiology summaryAbout 3,500 cervical cancer cases per year in Korea; CIN3 incidence markedly reduced after introduction of the HPV vaccine; national cervical cytology screening every 2 years from age 20.
5. Pathophysiology summaryHPV E6/E7 → loss of TP53 and RB1 function → telomerase activation → multistep progression CIN1→2→3→CIS; the squamocolumnar junction (SCJ) is the vulnerable site.
6. Symptoms summaryMostly asymptomatic; some have postcoital bleeding or abnormal vaginal discharge; most are detected on screening (Pap test).
7. Signs summaryHSIL on cervical cytology; acetowhite lesions and abnormal vascular patterns (punctation, mosaic) on colposcopy; ECC; Bethesda cytology reporting.
8. Screening summaryKorean national cervical cancer screening: cervical cytology every 2 years from age 20; abnormal findings of ASCUS, LSIL, or HSIL are linked to HPV testing and colposcopy.
9. Diagnosis summaryColposcopy-guided biopsy; endocervical curettage (ECC); HPV genotyping; p16 immunohistochemistry; conization is mandatory for AIS.
10. Treatment summaryLEEP (loop electrosurgical excision); cold-knife conization (CKC); cryotherapy (low-risk countries); CIN2 (observation possible in young women); hysterectomy for CIN3 after completion of childbearing.
11. Prognosis summary5-year recurrence after LEEP <15%; clearance of HPV after treatment is key to predicting recurrence; progression to invasive cervical cancer can be prevented.
12. Prevention summaryNational HPV vaccination (primary for girls aged 9-14, catch-up for adults); regular Pap tests; condom use; smoking cessation; minimizing the number of partners.

1. History

The history of carcinoma in situ of the cervix (CIN3/CIS, D06) goes hand in hand with the development of cytopathology and the discovery of human papillomavirus (HPV). In 1943, Greek-American physician George N. Papanicolaou and Herbert Traut formalized cervical cytology (the Pap smear) with the publication of Diagnosis of the Cervix and Vagina. The Papanicolaou smear went on to become one of the most successful cancer screening tests over the following decades, reducing cervical cancer mortality by more than 70%.

In 1953, Reagan introduced the concept of the cervical intraepithelial neoplasia (CIN) classification, which was later subdivided into CIN 1, 2, and 3. CIN 3 (= high-grade dysplasia + carcinoma in situ) was established as the direct precursor lesion of invasive cervical cancer. In the 1970s–80s, German virologist Harald zur Hausen isolated and cloned genital HPV and identified HPV types 16 and 18 as major causes of cervical cancer. For this work, zur Hausen received the 2008 Nobel Prize in Physiology or Medicine. The discovery of HPV subsequently led to the development of HPV vaccines (Gardasil 2006, Cervarix 2007), opening a new era of prevention of cervical precancerous lesions.

In terms of treatment, LEEP (Loop Electrosurgical Excision Procedure), first devised by the Chilean physician Renon in 1989, became established as the standard treatment replacing cold-knife conization. LEEP has the advantages that it can be performed in an outpatient setting under local anesthesia, allows histological examination, and has few bleeding and infection complications. In Korea, LEEP spread from the mid-1990s and is now the main treatment for cervical CIS/CIN3.

2. Causes

Human papillomavirus (HPV) accounts for more than 99% of the causes of cervical CIS. HPV types 16 and 18 are high-risk types that cause about 70-80% of cervical cancers and precancerous lesions. HPV types 31, 33, 45, 52, 58, and others are also included among the high-risk types. HPV is transmitted through sexual contact (vaginal, anal, and oral sex), and about 80% of sexually active adults are infected with HPV at least once in their lifetime. However, most (about 90%) HPV infections clear spontaneously through the immune system within 1-2 years.

Smoking: the risk of cervical CIS/cancer is 2-3 times higher in smokers than in nonsmokers. Tobacco carcinogens are known to directly damage the cervical mucosa and suppress local immune function, promoting persistent HPV infection. Immunosuppression: the risk of CIN3/CIS and cervical cancer increases 5-10-fold in patients with HIV infection (CD4 <200/μL) and those taking immunosuppressants after organ transplantation. Early first sexual experience and multiple sexual partners: because the squamo-columnar junction (SCJ) is more vulnerable during adolescence, early first sexual experience increases the risk of HPV infection. Long-term oral contraceptive use: use for 5 years or more increases the risk of cervical cancer (especially adenocarcinoma) about 1.5-2-fold, but the risk decreases after stopping. Low socioeconomic status and nutritional deficiency (lack of folate and vitamins A and C) are also related risk factors.

3. Genetics

Cervical CIS develops through the interaction of HPV viral genes (E6, E7) and host cell genes. The HPV16 E6 protein binds to the host cell tumor suppressor protein TP53 and promotes its degradation through the ubiquitin-proteasome pathway. Loss of TP53 suppresses the DNA damage response and apoptosis, allowing atypical cells to survive. The HPV18 E7 protein binds to and inactivates the cell cycle regulator pRb (retinoblastoma protein). Loss of pRb releases the E2F transcription factor, promoting cell cycle G1/S progression. These two mechanisms are the molecular core of the development of cervical CIS.

Telomerase reactivation: TERT expression increases in HPV-infected cells, leading to cellular immortalization. Somatic mutations: PIK3CA, KRAS, and TP53 mutations are more common in invasive cervical cancer but are also found in some cases at the CIS/CIN3 stage. PTEN loss activates the PI3K pathway. p16 overexpression: inactivation of pRb by HPV E7 increases p16 (CDKN2A) expression through feedback, so block-type p16 overexpression on immunohistochemistry is an important diagnostic aid for HPV-related CIN2/CIN3. Lynch syndrome (germline variants of MSH2, MLH1, MSH6, PMS2): mainly increases the risk of endometrial cancer, but there are reports that the risk of cervical adenocarcinoma (AIS) also increases.

4. General epidemiology

Cervical cancer (including invasive) is the fourth most common cancer in women worldwide, and inequality in cervical cancer deaths is severe in low-income countries. In Korea, annual new cases of cervical cancer are about 3,000-3,500 (2022), and incidence and mortality continue to decline with the national cervical cancer screening program and the introduction of HPV vaccines. The incidence of CIN3 (cervical CIS) is tens of times that of cervical cancer, with tens of thousands of new diagnoses per year in Korea.

Epidemiological impact of HPV vaccines: cohort studies of vaccination against HPV types 16/18 in the United Kingdom, Australia, Scotland, and elsewhere confirmed an 89% reduction in the incidence of CIN2 or higher lesions. Korea has provided national HPV vaccination for girls in the 6th grade of elementary school (age 12) since 2016, and the incidence of cervical CIS is expected to decrease greatly in the long term. Cervical CIS is most often diagnosed in sexually active women aged 20-45, with particularly high incidence at ages 25-35. As participation in national cervical cancer screening increases, the proportion detected at the CIS stage increases.

5. Pathophysiology

Cervical CIS begins at the squamo-columnar junction (SCJ)—the boundary where the squamous and columnar epithelia of the cervix meet. The SCJ is particularly vulnerable to HPV infection, and the basal cells in this area are the main targets of HPV infection.

After HPV infection, the viral genome exists in the cell nucleus as an episome or becomes integrated into the host chromosome. In the episomal form, the E2 protein suppresses E6/E7 expression so the infection is controlled, but with integration, E2 is lost and E6/E7 are overexpressed. When cell cycle checkpoints are paralyzed by E6 → TP53 degradation and E7 → pRb inactivation, atypical cells begin to proliferate. This process leads to multistep progression: CIN1 (mild dysplasia) → CIN2 (moderate dysplasia) → CIN3/CIS (high-grade dysplasia/carcinoma in situ) → invasive cancer. CIN1 mainly reflects transient HPV infection, with a spontaneous regression rate reaching 70-90%, while CIN3 left untreated for 5-10 years has a 30-50% rate of progression to invasive cancer. Adenocarcinoma in situ (AIS) arises in the columnar epithelium of the endocervix and is particularly associated with HPV type 18.

6. Symptoms

Cervical CIS (CIN3, D06) is mostly asymptomatic and is detected through cervical cytology (Pap smear) or HPV testing. This is the key reason cervical cancer screening is essential. The absence of symptoms does not mean the absence of a lesion at this stage.

Some patients may have the following symptoms. Postcoital bleeding: small amounts of bleeding after intercourse should raise suspicion of a cervical lesion, and immediate gynecological examination is needed. Abnormal vaginal discharge: there may be heavy, foul-smelling, or bloody discharge, but it is nonspecific. Intermenstrual bleeding: if irregular vaginal bleeding occurs, cervical evaluation is needed. These symptoms are more common in invasive cervical cancer than in CIS, and most cases at the CIS stage are asymptomatic. Therefore, participation in cervical cytology is key to detecting asymptomatic CIS.

7. Signs

Cervical cytology (Pap smear) results: a Bethesda system result of high-grade squamous intraepithelial lesion (HSIL, high-grade SIL) strongly suggests CIN2/3/CIS. ASC-H (atypical squamous cells, cannot exclude high grade) is also an indication for colposcopy. The positive predictive value of an HSIL cytology result is about 70-85%. Colposcopy findings: an acetowhite lesion appearing after application of 3-5% acetic acid suggests high-grade CIN/CIS, and the clearer the borders and the thicker the lesion, the higher the risk. Abnormal vascular patterns: punctation and mosaic are characteristic findings of high-grade lesions. On application of Lugol's iodine solution, normal mucosa appears brown and dysplastic mucosa appears yellow (iodine-negative). Endocervical curettage (ECC) evaluates the presence of lesions within the canal. Adenocarcinoma in situ (AIS) is difficult to diagnose because visual findings on colposcopy may be less clear than the cytological abnormality.

8. Screening

Korean national cervical cancer screening: free cervical cytology (Pap smear) is provided every 2 years to women aged 20 and older. Participation in national cancer screening is about 55-65%, and cervical cancer mortality is significantly lower in women who participate in screening than in those who do not. Abnormal findings (ASCUS, LSIL, HSIL, AGC, or worse) are linked to additional tests (HPV testing, colposcopy, biopsy).

HPV testing (co-testing or HPV primary screening): performing HPV DNA testing together with the Pap smear (co-testing) or alone (HPV primary screening) increases the sensitivity for detecting cervical cancer precursor lesions, particularly in women aged 30 and older. If high-risk HPV is negative, the retesting interval can be extended to 5 years. ASCUS management algorithm: for an ASCUS result, reflex HPV test → colposcopy if HPV positive → cytology after 1 year if negative. HSIL management: choose between immediate colposcopy or immediate LEEP (immediate excision). In pregnant women and adolescents (aged 24 or younger), prioritizing observation is also possible.

9. Diagnosis

Confirmation of cervical CIS (CIN3) requires histopathological confirmation by tissue biopsy. Colposcopy-directed biopsy is the standard diagnostic method. Tissue is taken from the most severe area of the acetowhite lesion with a punch biopsy or large biopsy forceps. Endocervical curettage (ECC): performed together with colposcopy to evaluate for lesions within the canal. ECC is not performed in pregnant women. LEEP excisional biopsy (diagnostic excision): when a high-grade lesion has been confirmed by colposcopy and biopsy but its extent is unclear or AIS is suspected, diagnostic LEEP (or cold-knife conization) is performed.

HPV genotyping: identifies which high-risk HPV type is present. With HPV type 16/18 infection, the risk of CIN3 and invasive cancer is higher than with other types, so immediate colposcopy is recommended. Immunohistochemistry: block-type p16 (CDKN2A) overexpression is a specific marker of HPV-associated high-grade CIN/CIS; Ki-67 proliferation index; p63 (squamous cell marker). In the diagnosis of AIS, immunohistochemistry for a glandular marker (carcinoembryonic antigen, CEA) is helpful.

10. Treatment

Treatment of cervical CIS/CIN3 is determined by the extent of the lesion, the patient's age, pregnancy status, and whether fertility is to be preserved.

LEEP (loop electrosurgical excision procedure): the most commonly used standard treatment, performed in an outpatient setting under local anesthesia. A loop electrode is used to excise a cone of cervical tissue that includes the squamocolumnar junction and the transformation zone. The treatment success rate (HPV clearance + histologically negative) is about 90-95%. Effect on pregnancy: the risk of preterm labor and preterm birth after LEEP is reported to increase somewhat, but this is weighed against the risk of not treating. Cold-knife conization (CKC): performed in the operating room under general anesthesia; recommended for AIS or when the extent of endocervical lesions is unclear. Allows wider margins. Cryotherapy: used in resource-limited settings for CIN2 when the lesion is small, fully visualized, and without endocervical involvement. In developed countries it has been replaced by LEEP. Active surveillance: for CIN2 in young women under 25, follow-up with Pap smear + HPV testing every 6 months in anticipation of spontaneous HPV clearance is possible. Hysterectomy: considered for CIN3 when childbearing is complete, for repeatedly positive margins after LEEP, and for recurrent CIN3. For AIS, some guidelines recommend hysterectomy even after negative margins are confirmed.

11. Prognosis

Cervical CIS (CIN3) has a very favorable prognosis when appropriately treated. Recurrence rate after LEEP: 5-year recurrence (CIN2 or higher) is about 5-15%, and much lower with negative margins (2-5%). With positive margins, the recurrence rate is significantly higher at 17-25%, so additional treatment or close follow-up is needed. HPV clearance is the most important indicator of treatment success. If HPV becomes negative 6-12 months after treatment, the risk of recurrence decreases markedly. Follow-up after treatment: Pap smear + HPV testing every 6 months for the first 1-2 years, then annually. Because the risk of cervical cancer remains higher than in the general population for at least 20 years after treatment, long-term follow-up is needed. AIS (adenocarcinoma in situ): the recurrence rate after LEEP or excision is higher than for squamous CIS (about 10-20%), and because of the risk of residual disease, hysterectomy tends to be preferred.

12. Prevention

National HPV vaccination is the most effective primary prevention for cervical CIS. In Korea, the quadrivalent Gardasil (HPV types 6/11/16/18) or 9-valent Gardasil 9 (HPV types 6/11/16/18/31/33/45/52/58) vaccine is provided free as a national vaccination for girls in the 6th grade of elementary school (age 12). As of 2024, catch-up vaccination for adults is also supported. In clinical trials, the vaccine's efficacy in preventing CIN2 or higher reaches 90-100% in women never infected with HPV types 16/18.

Regular cervical cytology: steady participation in Korean national cervical cancer screening (every 2 years from age 20) is key to early detection at the CIS stage. Condom use: does not provide complete protection but reduces the risk of HPV transmission by about 70%. Smoking cessation: smoking increases the risk of CIN3/CIS, so smoking cessation is recommended. Minimizing the number of sexual partners: multiple sexual partners increase the risk of HPV exposure. Maintaining immune status: in people with HIV infection and immunosuppressed patients, a shorter interval for regular cervical screening is maintained (every 6-12 months).


13. References

  1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-350.
  2. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941;42(2):193-206.
  3. Reagan JW, Seidemann IL, Saracusa Y. The cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of the uterine cervix. Cancer. 1953;6(2):224-235.
  4. Kyrgiou M, et al. Adverse effects of treatment for cervical intraepithelial neoplasia on neonatal outcome: meta-analysis. BMJ. 2006;332(7556):1308-1312.
  5. Arbyn M, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(5):CD009069.
  6. National Cancer Center. Recommendations for Cervical Cancer Screening. National Cancer Center, 2023.
  7. NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer. Version 1.2024. National Comprehensive Cancer Network, 2024.
  8. Massad LS, et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1-27.
  9. Cervical Cancer Screening: Updated Guidance from the World Health Organization. WHO, 2021.
  10. Korea Disease Control and Prevention Agency (KDCA). Guide to the National HPV Immunization Program. Korea Disease Control and Prevention Agency (KDCA), 2024.